Approved Projects

Seqex devices have been approved for treatment of osteoarticular disorders since 1997 (available for purchase since 1999). Over the years numerous medical doctors who administered the treatment noted possible beneficial effects in other medical contexts, often as already discussed in international scientific publications. These observations provided the inspiration for the design of the research projects listed here, all approved by hospital ethics committees. The following documents therefore might indicate possible future fields of application for Seqex technology. However, the present research projects do not in any way represent therapeutic indications in substitution of medical treatments currently approved by the Ministry of Health for the pathologies in question.

» Reducing the side-effects of chemotherapy
Project title: Use of Seqex equipment to generate ion cyclotron resonance fields in the bodies of patients as an adjuvant therapy, with the aim of reducing the side-effects of chemotherapy.
Approval date: 4 July 2003
Project leader: Dr. Edoardo Rossi
Responsible body: San. Martino University Hospital of Genova – IST – National Institute for Cancer Research Section 2 Regional Ethical Committee
Status: Completed
Attachments: Ethical Committee report
Further information: minutes of Sibe Congress 2007
» Anti-oxidant effects in chemo-radiotherapy
Project title: Use of supporting anti-oxidant therapy, both physical (ion cyclotron resonance) and nutritional associated with nutritional counselling, with the aim of reducing the effects of toxicity in onco-hematological patients subject to chemo-radiotherapy.
Approvato in data: 10 March 2009
Project leader: Dr. Edoardo Rossi
Responsible body: San. Martino University Hospital of Genova – IST -National Institute for Cancer Research Section 2 Regional Ethical Committee
Status: Completed
Attachments: Ethical Committee report
Further information: minutes of Sibe Congress 2010
» Cardiovascular risk protection
Project title: Assessing the potential protective effects of extremely low frequency electromagnetic fields (ELF-EMF) against cardiovascular risk.
Approval date: April 2010
Project leader: Dr. Edoardo Rossi
Responsible body: San. Martino University Hospital of Genova – IST -National Institute for Cancer Research Section 2 Regional Ethical Committee
Status: Underway
Attachments: Ethical Committee report